Insulin Resistance and GLP-1 Receptor Signaling: Cell Model Research into Incretin Biology and Glucose Homeostasis

Insulin Resistance at the Cellular Level: IRS-1 Phosphorylation and PI3K/Akt Pathway Disruption

Insulin resistance — the condition in which target cells fail to respond normally to insulin signaling — is best understood mechanistically at the level of the insulin receptor substrate (IRS) proteins. When insulin binds its receptor (IR, a receptor tyrosine kinase), it triggers autophosphorylation of cytoplasmic tyrosine residues on the receptor beta-subunit, which then recruits and tyrosine-phosphorylates IRS-1 and IRS-2. Tyrosine-phosphorylated IRS-1 serves as a docking scaffold for the p85 regulatory subunit of phosphoinositide 3-kinase (PI3K), which activates the catalytic p110 subunit to phosphorylate PIP2 to PIP3 at the plasma membrane.

PIP3 recruits PDK1, which phosphorylates Akt (protein kinase B) at Thr308; mTORC2 provides additional activating phosphorylation at Ser473. Fully activated Akt then mediates the major metabolic actions of insulin: GLUT4 vesicle translocation, glycogen synthase activation (via GSK-3beta inhibition), and suppression of hepatic gluconeogenesis (via FOXO1 phosphorylation and nuclear exclusion).

Insulin resistance disrupts this cascade primarily through serine phosphorylation of IRS-1 at inhibitory sites (particularly Ser307 in rodents, Ser312 in humans) by stress kinases including JNK (c-Jun N-terminal kinase), IKKβ, mTOR/S6K1, and PKC isoforms activated by lipid intermediates (diacylglycerol, ceramides). Serine-phosphorylated IRS-1 cannot efficiently dock PI3K, uncoupling IR activation from downstream Akt signaling. This is the molecular basis for insulin resistance inducible in cell culture models using saturated fatty acids, chronic hyperinsulinemia, or inflammatory cytokines.

Inducing and Measuring Insulin Resistance in Cell Culture Models

Researchers studying GLP-1R agonists in the context of insulin resistance require reproducible in vitro models of impaired insulin signaling. Several established induction protocols are used:

• Palmitate (palmitic acid) loading: BSA-conjugated palmitate (0.4–0.75 mM) applied to hepatocytes or myotubes for 16–24 hours induces ceramide accumulation, JNK activation, and IRS-1 serine phosphorylation. This is the most widely used lipotoxicity model and produces robust, reproducible insulin resistance in HepG2 and primary hepatocyte preparations.
• Chronic hyperinsulinemia: pretreatment with supraphysiological insulin concentrations (100–1000 nM) for 24–48 hours downregulates insulin receptor expression and activates S6K1-mediated IRS-1 Ser307 phosphorylation, producing a state of insulin-induced insulin resistance that models chronic hyperinsulinemic states.
• TNF-alpha treatment: 10–50 ng/mL TNF-alpha activates JNK and IKKβ, phosphorylating IRS-1 at inhibitory serine residues and reducing insulin-stimulated Akt phosphorylation. This cytokine-induced resistance model is useful for studying the inflammatory component of metabolic dysfunction.
• High glucose / glucolipotoxicity: combined high glucose (25–33 mM) and palmitate treatment models the dual lipid and glucose excess of metabolic disease states; more severe insulin resistance than either stimulus alone.

Standard readouts for insulin resistance induction include: phospho-IRS-1 (Ser307/Ser312) by Western blot, phospho-Akt (Ser473/Thr308) following acute insulin stimulation, 2-NBDG glucose uptake, and GLUT4 surface translocation assays. A well-characterized insulin-resistant cell model should show significantly blunted insulin-stimulated pAkt relative to non-resistant controls before GLP-1R agonist interventions are introduced.

GLP-1 Receptor Activation: cAMP, PKA, and Glucose-Dependent Insulin Secretion

The glucagon-like peptide-1 receptor (GLP-1R) is a class B G protein-coupled receptor (GPCR) that signals primarily through Gαs coupling to adenylyl cyclase, generating cyclic AMP (cAMP) from ATP. Elevated intracellular cAMP activates two major effectors: protein kinase A (PKA) and the exchange protein directly activated by cAMP (Epac2 / RAPGEF4).

In pancreatic beta cells, GLP-1R-driven cAMP elevation produces a cascade of insulin secretion-amplifying effects:

• PKA phosphorylates and potentiates voltage-gated L-type Ca²⁺ channels, increasing Ca²⁺ influx during membrane depolarization triggered by glucose-derived ATP closure of K_ATP channels
• Epac2 activates Rap1 GTPase signaling, promoting insulin granule recruitment to the plasma membrane and augmenting the readily releasable pool of secretory vesicles
• PKA phosphorylates SNAP-25 and other SNARE complex components, facilitating vesicle fusion with the plasma membrane
• cAMP signaling enhances transcription of insulin gene (INS) and PDX-1 (pancreatic duodenal homeobox-1) — key beta-cell identity transcription factor — over longer time scales

Critically, GLP-1R-mediated insulin secretion is glucose-dependent: at low glucose concentrations (<4 mM), GLP-1R activation does not trigger insulin secretion because K_ATP channels remain open (membrane hyperpolarized) and voltage-gated Ca²⁺ channels are not recruited. This glucose-dependency is a defining pharmacological property distinguishing GLP-1R agonists from sulfonylureas (which close K_ATP directly, releasing insulin regardless of glucose) and is an important control variable in cell-based GSIS assays.

HepG2 and Primary Hepatocyte Models of Insulin Resistance

The liver is a critical site of insulin action — insulin suppresses hepatic glucose output (gluconeogenesis and glycogenolysis) via the PI3K/Akt/FOXO1 axis. Hepatic insulin resistance, in which this suppression is impaired, is a key contributor to fasting hyperglycemia in metabolic disease models.

HepG2 is a human hepatocellular carcinoma cell line widely used in metabolic research due to its maintained hepatocyte-like gene expression profile and metabolic activity. Key features for insulin resistance research:

• Express functional insulin receptor, IRS-1, IRS-2, and downstream Akt signaling
• Perform gluconeogenesis (detectable by glucose output assay following cAMP stimulation with 8-Br-cAMP to activate PEPCK/G6Pase)
• Respond to palmitate loading with IRS-1 serine phosphorylation and reduced insulin-stimulated Akt activity
• Express GLP-1R at low levels — hepatic GLP-1R expression and direct hepatic GLP-1 action remains controversial in the literature, making hepatocyte-based GLP-1 research mechanistically complex

Primary human hepatocytes (PHH), isolated from donor liver by two-step collagenase perfusion and maintained in sandwich culture between two layers of Matrigel or collagen, are the gold standard for hepatic metabolism research. PHH maintain cytochrome P450 activity, transporter expression, and gluconeogenic enzyme activity far better than HepG2 cells but are expensive, limited in supply, and show donor-to-donor variability. For GLP-1R biology specifically, PHH are preferred when investigating indirect hepatic effects mediated by insulin sensitization in peripheral tissues.

Pancreatic Islet and Beta-Cell Models for GLP-1R Research

The pancreatic beta cell is the canonical GLP-1R-expressing cell type and the primary site of incretin action on insulin secretion. In vitro models available for GLP-1R research span a range of physiological fidelity:

• INS-1 / INS-1E (rat insulinoma): the most commonly used beta-cell line; maintains glucose-stimulated insulin secretion (GSIS), expresses GLP-1R endogenously, and responds to GLP-1R agonists with cAMP elevation and amplified GSIS. INS-1E is the more glucose-responsive sub-clone and is preferred for secretion studies.
• MIN6 (mouse insulinoma): another glucose-responsive beta-cell line with endogenous GLP-1R expression; maintains higher GSIS capacity than INS-1 in some experimental contexts
• EndoC-βH1/βH3 (human): human beta-cell lines derived from fetal pancreas; currently the most physiologically relevant human beta-cell models available, expressing human GLP-1R and responding to GLP-1R agonists with human-relevant secretory kinetics
• Isolated primary islets: mouse, rat, or human donor islets maintained in suspension culture; functionally intact three-dimensional micro-organs containing alpha, beta, delta, and PP cells in native architecture. Primary islets represent the highest physiological fidelity for GLP-1R secretion research but require specialized isolation expertise and are limited in quantity.

For GSIS assays specifically, cells are glucose-starved (2.8 mM, sub-stimulatory) for 60–120 minutes, then exposed to stimulatory glucose (16.7 mM) with or without GLP-1R agonist for 30–60 minutes; supernatant insulin is quantified by ELISA or radioimmunoassay. The stimulation index (insulin secreted at high glucose / insulin at basal glucose) is the primary efficacy metric.

Glucose Uptake Assays in Insulin-Resistant Muscle Cell Lines

While GLP-1R is most highly expressed in pancreatic islets and enteroendocrine cells, GLP-1R agonist research in the context of skeletal muscle insulin resistance is an active area — both for direct GLP-1R effects in muscle (where receptor expression is debated) and for indirect effects mediated through improved insulin sensitivity following beta-cell rescue.

Glucose uptake assay protocols in insulin-resistant C2C12 myotubes:

• Differentiate C2C12 myoblasts to myotubes over 5–7 days in 2% horse serum medium
• Induce insulin resistance by 16-hour palmitate (0.5 mM, BSA-conjugated) or 48-hour chronic insulin (100 nM) pretreatment; verify resistance by blunted pAkt(Ser473) response to 100 nM insulin challenge
• Wash out resistor agent; apply GLP-1R agonist treatment for 30–60 minutes (or vehicle control)
• Perform acute insulin stimulation (10–100 nM, 20 minutes) to assess whether GLP-1R agonist pretreatment has shifted insulin sensitivity
• Measure 2-NBDG (100 μM, 20-minute pulse) uptake by flow cytometry or fluorescence plate reader; alternatively, use radiolabeled 2-[¹⁴C]-deoxyglucose scintillation counting for greater sensitivity

A key control consideration: GLP-1R agonists at concentrations used in cell culture may exert cAMP-mediated effects on glucose uptake independently of insulin sensitization, since cAMP/PKA signaling can directly promote GLUT4 translocation in some cell systems. Including PKA inhibitor H89 or Epac-selective cAMP analog 8-CPT-2Me-cAMP in parallel wells helps dissect PKA-dependent vs. Epac-dependent components of any observed effect.

Comparing GLP-1 Agonists in GSIS Assays: Semaglutide vs. Tirzepatide

A scientifically productive use of research-grade GLP-1R agonists is comparative pharmacology in standardized cell-based assay systems. Semaglutide is a selective GLP-1R agonist, while tirzepatide is a dual GIP/GLP-1 receptor co-agonist — each produces distinct signaling profiles that can be interrogated in vitro.

Key differences relevant to cell-based research design:

• Receptor selectivity: semaglutide acts exclusively at GLP-1R; tirzepatide activates both GLP-1R and GIPR (glucose-dependent insulinotropic polypeptide receptor). In cell lines expressing only GLP-1R (e.g., GLP-1R-transfected HEK293), tirzepatide's GIPR component contributes no activity; in islet preparations expressing both receptors natively, differential signaling is preserved.
• cAMP efficacy: tirzepatide has been characterized as a functionally biased agonist at GLP-1R — it produces lower maximal cAMP accumulation than native GLP-1 or semaglutide at GLP-1R, but higher cAMP at GIPR. In GLP-1R-only cAMP assays (HTRF cAMP or GloSensor), tirzepatide may appear as a partial agonist relative to semaglutide when GLP-1R is the only receptor expressed.
• Beta-arrestin recruitment: GLP-1R signaling through beta-arrestin (rather than Gαs) mediates receptor internalization and desensitization. Biased agonists that preferentially engage Gαs over beta-arrestin may sustain cAMP signaling longer; BRET-based beta-arrestin recruitment assays can measure this in transfected cell systems.
• GSIS amplification: in primary islet or INS-1E GSIS assays, both semaglutide and tirzepatide amplify glucose-stimulated insulin secretion, but tirzepatide's dual receptor engagement may produce additive or synergistic effects on secretion in preparations expressing both GLP-1R and GIPR at physiological ratios.

Designing comparative GSIS experiments requires careful attention to compound concentrations: given dramatic differences in receptor binding affinity and albumin binding (both compounds are highly protein-bound fatty-acid conjugates), free fraction concentrations in serum-containing assay buffers may diverge significantly from nominal added concentrations. Conducting receptor saturation experiments (10-point concentration-response curves) before running comparative efficacy assays is strongly recommended for rigorous pharmacological characterization in any new cell system.